Fig. 10From: The efficacy of tixagevimab/cilgavimab (Evusheld) in prophylaxis and treatment of COVID-19 in immunocompromised patients: a systematic review and meta-analysisThe forest plot reveals the correlation between Evusheld administration as a treatment and the mortality rate of COVID-19 infectionsBack to article page